Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Belzutifan in Hepatic Impairment
NCT04995484Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belzutifan in renal cell carcinoma (RCC) and von Hippel–Lindau disease (VHL) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity at 120 hours, Area Under the Concentration-Time Curve From Time 0 to 24 Hours and 3 more. Started Jun 2022; status: completed.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT04995484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995484.